Bayle Arnaud, Basile Debora, Garinet Simon, Rance Bastien, Laurent-Puig Pierre, Blons Hélène, Taieb Julien, Perkins Geraldine
Institut du Cancer Paris CARPEM, AP-HP, AP-HP.Centre, Department of Hepatogastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015 Paris, France.
Institut du Cancer Paris CARPEM, AP-HP, AP-HP. Centre, Department of Biochemistry, Hôpital Européen Georges Pompidou, 75015 Paris, France.
Cancers (Basel). 2021 Nov 17;13(22):5750. doi: 10.3390/cancers13225750.
In digestive oncology, the clinical impact of targeted next-generation sequencing (NGS) in routine practice should be addressed. In this work, we studied the impact of a 22-gene NGS amplicon-based panel with Ion Torrent Proton Sequencing, prospectively performed in routine practice. We analyzed the results of extended molecular testing, beyond and in metastatic colorectal cancer (mCRC) patients in a single-center, retrospective, observational study of consecutive mCRC patients followed up at the Georges Pompidou European Hospital between January 2016 and December 2018. Overall, 210 patients with mCRC were included. Median follow-up was 25.4 months (IQR: 14.9-39.5). The three most frequently mutated genes were: (63%), (41%) and (19%). A positive association was found between overall survival and performance status (PS) ≥ 2 (HR: 4.91 (1.84-13.1); = 0.001) and differentiation (HR: 4.70 (1.51-14.6); = 0.007) in multivariate analysis. The NGS panel enabled five patients to access a targeted therapy not currently registered for CRC. In conclusion, targeted NGS panels in mCRC are feasible in routine practice, but need to be regularly updated and in-depth studies are needed to better analyze the prognostic factors.
在消化肿瘤学领域，应探讨靶向新一代测序（NGS）在常规临床实践中的影响。在本研究中，我们使用Ion Torrent Proton测序技术，对一个包含22个基因的基于扩增子的NGS检测板进行了研究，该研究在常规临床实践中前瞻性开展。我们在一项单中心、回顾性、观察性研究中，分析了2016年1月至2018年12月期间在乔治·蓬皮杜欧洲医院接受随访的连续性转移性结直肠癌（mCRC）患者的扩展分子检测结果，这些检测超出了常规检测范围。总共纳入了210例mCRC患者。中位随访时间为25.4个月（四分位间距：14.9 - 39.5个月）。三个最常发生突变的基因分别是：（63%）、（41%）和（19%）。在多变量分析中，发现总生存期与体能状态（PS）≥2（风险比：4.91（1.84 - 13.1）；P = 0.001）以及肿瘤分化程度（风险比：4.70（1.51 - 14.6）；P = 0.007）之间存在正相关。该NGS检测板使5例患者能够接受目前未注册用于CRC的靶向治疗。总之，mCRC中的靶向NGS检测板在常规临床实践中是可行的，但需要定期更新，并且需要进行深入研究以更好地分析预后因素。 （注：原文中部分基因名称未给出具体内容，用括号代替）
